The abstract is read at the publisher; the summary is JClub's.
Mild immune-related hepatitis (grade 1–2) in 3261 East Asian lung cancer patients treated with ICIs predicts longer overall survival, with onset at 2.17 months.
- Why it matters: Immune-related adverse events and outcomes differ by ancestry, but Asian-specific biomarkers for immune-related hepatitis and survival risk are not well validated.
- What they did: In a single-center retrospective cohort (2018–2023), 380 IRH and 248 IRP cases were randomly matched to controls for HLA genotyping (1793 total), using time-varying Cox and landmark analyses.
- The result: HLA-DQB1*06:01 was linked to poorer overall survival (p=0.0004, FDR 0.03) regardless of IRH, while no HLA variants were associated with developing IRH or IRP.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.